Publication Author: Westerhout CM
Filter by Author:
Phenomapping in Heart Failure With Reduced Ejection Fraction to Identify Subpopulations With High Residual Risk: A VICTORIA Substudy.
Shah P, Zheng Y, Pieske B, Melenovsky V, Lam CSP, Sliwa K, Butler J, Ezekowitz JA, deFilippi CR, O'Connor CM, Sandhu RK, Roessig L, Tromp J, Westerhout CM, Voors AA, Armstrong PW; VICTORIA Study Group.
Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.
Westerhout CM, Alemayehu W, Cohen-Solal A, Lam CSP, Ezekowitz JA, Corda S, McMullan CJ, O'Connor CM, Armstrong PW; VICTORIA Study Group.
Assessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification.
O'Connor CM, Rathwell S, Mehrotra DV, Corda S, McMullan CJ, Lam CSP, Ezekowitz JA, Piekse B, Hernandez AF, Anstrom KJ, Mentz RJ, deFilippi CR, Voors A, Ponikowski P, Butler J, Westerhout CM, Armstrong PW; VICTORIA Study Group.
Geographic Variation and Human Development Index in Heart Failure With Reduced Ejection Fraction: Insights From VICTORIA.
Cohen-Solal A, Alemayehu W, Lam CSP, Tsutsui H, Zhang J, Godoy-Palomino A, Tziakas DN, Corda S, McMullan CJ, Ezekowitz JA, Hernandez AF, Pieske B, O'Connor CM, Westerhout CM, Armstrong PW; VICTORIA Study Group.
Implantable cardioverter-defibrillators in ischaemic versus non-ischaemic heart failure: Insights from the VICTORIA trial.
Gouda P, Alemayehu W, Voors AA, Lam CSP, Ezekowitz J, Pieske B, Butler J, Westerhout CM, Yogasundaram H, Sandhu RK, Armstrong PW; on behalf of the VICTORIA Study Group.
Pharmaco-invasive Strategy and Dosing of Tenecteplase in STEMI Patients 60 to <75 Years: An Inter-trial Comparison of the STREAM-1 and STREAM-2 Trials: Comparison of Patients 60 to <75 Years in STREAM-1 and -2.
Bainey KR, Welsh RC, Zheng Y, Arias-Mendoza A, Ristić AD, Averkov OV, Lambert Y, Temple T, Ly E, Bogaerts K, Sinnaeve P, Westerhout CM, Van de Werf F, Armstrong PW; STREAM-2 Investigators.
Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2.
Bainey KR, Welsh RC, Zheng Y, Arias-Mendoza A, Ristic AD, Averkov OV, Lambert Y, Kerr Saraiva JF, Sepulveda P, Rosell-Ortiz F, French JK, Musić LB, Temple T, Ly E, Bogaerts K, Sinnaeve PR, Danays T, Westerhout CM, Van de Werf F, Armstrong PW; STREAM-2 Investigators.
Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.
deFilippi CR, Shah P, Shah SJ, Alemayehu W, Lam CSP, Butler J, Roessig L, O'Connor CM, Westerhout CM, Armstrong PW; VITALITY-HFpEF Study Group.
Comparing Analytical Methods for Composite Endpoints in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) Trial.
Westerhout CM, Rathwell S, Anstrom KJ, Hernandez AF, Ponikowski P, Ezekowitz JA, Voors AA, Felker GM, Bakal JA, Blaustein RO, Nkulikiyinka R, O'Connor CM, Armstrong PW; VICTORIA Study Group.
Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial
Tromp J, Lam CSP, Alemayehu W, de Filippi CR, Melenovský V, Sliwa K, Lopatin Y, Arango JL, Bahit MC, Roessig L, O'Connor CM, Shah P, Westerhout CM, Voors AA, Pieske B, Armstrong PW; VICTORIA Study Group.
Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.
Ezekowitz J, Alemayehu W, Edelmann F, Ponikowski P, Lam CSP, O'Connor CM, Butler J, Corda S, McMullan CJ, Westerhout CM, Voors AA, Mentz RJ, Armstrong PW; VICTORIA Study Group.
Relationship Between Baseline Electrocardiographic Measurements and Outcomes in Patients with High-Risk Heart Failure: Insights from the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.
Yogasundaram H, Zheng Y, Ly E, Ezekowitz JA, Ponikowski P, Lam CSP, O'Connor C, Blaustein RO, Roessig L, Temple T, Westerhout CM, Armstrong PW, Sandhu RK, VICTORIA Study Group.
Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial.
Lam CSP, Piña IL, Zheng Y, Bonderman D, Pouleur AC, Saldarriaga C, Pieske B, Blaustein RO, Nkulikiyinka R, Westerhout CM, Armstrong PW, VICTORIA Study Group.
Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat.
Armstrong PA, Zheng Y, Lund LH, Butler J, Troughton RW, Emdin M, Lam CSP, Ponikowski P, Blaustein RO, O'Connor CM, Roessig L, Voors AA, Ezekowitz JA, Westerhout CM, VICTORIA Study Group.
STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial
Van de Werf F, Ristic AD, Averkov OV, AriasMendoza A, Lambert Y, Kerr Saraiva JF, Sepulveda P, Rosell-Ortiz F, French JK, Music LB, Vandenberghe K, Bogaerts K, Westerhout CM, Pages A, Danays T, Bainey KR, Sinnaeve P, Goldstein P, Welsh RC, Armstrong PW, STREAM-2 Investigators.
Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
Ezekowitz JA, McMullan CJ, Westerhout CM, Pina IL, Lopez-Sendon J, Anstrom KJ, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Koglin J, Armstrong PW, Butler J, VICTORIA Study Group.
Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.
Butler J, Zheng Y, Khan MS, Bonderman D, Lund LH, deFilippi CR, Blaustein RO, Ezekowitz JA, Freitas C, Hernandez AF, O'Connor CM, Voors AA, Westerhout CM, Lam CSP, Armstrong PW; VICTORIA Study Group.
Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Echocardiographic Substudy.
Pieske B, Pieske-Kraigher E, Lam CSP, Melenovský V, Sliwa K, Lopatin Y, Arango JL, Bahit MC, O'Connor CM, Patel MJ, Roessig L, Morris DA, Kropf M, Westerhout CM, Zheng Y, Armstrong PW; VICTORIA Study Group.
Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.
Kaul P, Rathwell S, Lam CSP, Westerhout CM, Spertus JA, Anstrom KJ, Blaustein RO, Ezekowitz JA, Pieske B, Roessig L, Butler J, Armstrong PW; VITALITY-HFpEF Study Group.
The empirical estimate of the survival and variance using a weighted composite endpoint.
Nabipoor M, Westerhout CM, Rathwell S, Bakal JA.
